Equities

Seelos Therapeutics Inc

Seelos Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.9069
  • Today's Change-0.053 / -5.53%
  • Shares traded277.76k
  • 1 Year change-99.66%
  • Beta1.9339
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

  • Revenue in USD (TTM)1.97m
  • Net income in USD-27.12m
  • Incorporated1987
  • Employees10.00
  • Location
    Seelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
  • Phone+1 (646) 293-2100
  • Fax+1 (858) 436-8155
  • Websitehttps://seelostherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AgriFORCE Growing Systems Ltd16.28k-13.34m2.13m7.00--0.2068--130.98-10.78-10.780.00390.3960.0009--0.4432,325.71-74.39-78.95-100.77-109.8616.58---81,946.25-243,182.500.8186-1.300.1913------8.85--48.61--
American Green Inc-100.00bn-100.00bn2.14m6.00------------------------------------------------------------
Finch Therapeutics Group Inc0.00-16.28m2.31m18.00--0.1215-----10.14-10.140.0011.860.00-------25.22---28.97--------------0.00---87.57--34.80------
CTT Pharmaceutical Holdings Inc0.00-1.67m2.31m0.00--1.30-----0.0822-0.08220.000.03460.00-------317.2813.49-448.83304.48------------0.00-------3,454.52------
Resonate Blends Inc101.41k-4.72m2.34m6.00------23.05-0.0537-0.05370.0012-0.00070.0328-------152.56-680.29-----34.87-78.88-4,657.83-12,895.26---0.74131.02---66.73-56.57-316.63------
Seelos Therapeutics Inc1.97m-27.12m2.36m10.00------1.20-44.59-44.592.16-17.360.1449--2.24131,600.00-198.99-180.05---386.76-----1,373.61-9,612.88------------48.48------
Axim Biotechnologies Inc85.35k-5.59m2.38m6.00------27.93-0.0249-0.02490.0003-0.02680.0214----14,225.00-140.13-154.34---390.73-----6,548.75-36,362.71---1.16----345.05-27.38-29.10------
Agile Therapeutics Inc21.50m-7.79m2.43m19.00------0.1132-3.65-3.656.98-1.511.632.905.421,131,316.00-59.25-94.24---142.6259.73---36.26-513.500.3843------80.02--43.08------
Aoxing Pharmaceutical Company Inc30.11m-1.46m2.46m339.00--0.0287--0.0816-0.0192-0.01920.39510.25070.4962.322.56---2.41-14.54-7.06-35.4576.1968.51-4.85-37.690.73680.33870.6052--26.8837.20-62.49---38.80--
Aclarion Inc60.05k-6.13m2.46m6.00--0.8563--40.97-7.41-7.410.03410.35020.0215--3.5010,008.33-219.26---337.53---29.49---10,203.20------0.211--24.75--34.38------
Cyclacel Pharmaceuticals Inc449.00k-19.85m2.47m12.00------5.51-21.99-21.990.4636-1.670.0318--0.1204---139.57-57.58-314.22-69.81-----4,386.86-18,789.29---128.51------22.87-6.34---31.23--
cbdMD Inc21.58m-25.65m2.51m52.00--0.6413--0.1164-19.96-19.969.271.010.89492.0921.27415,039.60-89.78-38.59-118.26-41.5062.7063.80-100.33-87.980.6107-3.010.4668---31.77120.9163.64---4.95--
Eloxx Pharmaceuticals Inc0.00-20.48m2.51m18.00---------9.06-9.060.00-6.530.00----0.00-124.43-115.27---155.33-----------16.69--------45.95---22.56--
Qrons Inc0.00-763.52k2.53m2.00---------0.0562-0.05620.00-0.10780.00----0.00-18,782.78-1,513.45---------------19.02---------7.61------
Data as of Jun 14 2024. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.